Period of time： 2014年1期
Publisher： Informa Healthcare
Founded in： 1996
Total resources： 42
ISSN： 1472-8214
Subject： R9 Pharmacy
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Expert Opinion on Emerging Drugs,volume 6,issue 1
Menu
Access to resources
Recommend
The role of endothelin receptor antagonists in cardiovascular pharmacotherapy
By Münter K.,Kirchengast M. in (2001)
Expert Opinion on Emerging Drugs,volume 6,issue 1 , Vol. 6, Iss. 1, 2001-04 , pp.Emerging therapies for hepatitis C virus infection
Expert Opinion on Emerging Drugs,volume 6,issue 1 , Vol. 6, Iss. 1, 2001-04 , pp.Oxazolidinones: new players in the battle against multi-resistant Gram-positive bacteria
By Kaatz G.W.,Rybak M.J. in (2001)
Expert Opinion on Emerging Drugs,volume 6,issue 1 , Vol. 6, Iss. 1, 2001-04 , pp.Serotonergic modulation and irritable bowel syndrome
Expert Opinion on Emerging Drugs,volume 6,issue 1 , Vol. 6, Iss. 1, 2001-04 , pp.Clinical trials of a new class of therapeutic agents: antisense oligonucleotides
By Galderisi U.,Cipollaro M.,Cascino A. in (2001)
Expert Opinion on Emerging Drugs,volume 6,issue 1 , Vol. 6, Iss. 1, 2001-04 , pp.Caspase inhibitors as neuroprotective agents
By Legos J.J.,Lee D.,Erhardt J.A. in (2001)
Expert Opinion on Emerging Drugs,volume 6,issue 1 , Vol. 6, Iss. 1, 2001-04 , pp.The effect of HMG-CoA reductase inhibitors on chronic allograft rejection
Expert Opinion on Emerging Drugs,volume 6,issue 1 , Vol. 6, Iss. 1, 2001-04 , pp.Emerging anticoagulant and thrombolytic drugs
By Iqbal O.,Aziz S.,Hoppensteadt D.A.,Ahmad S.,Walenga J.M.,Bakhos M.,Fareed J. in (2001)
Expert Opinion on Emerging Drugs,volume 6,issue 1 , Vol. 6, Iss. 1, 2001-04 , pp.Therapeutic potential of oestrogen receptor ligands in development for osteoporosis
By Cho C.H.,Nuttall M.E. in (2001)
Expert Opinion on Emerging Drugs,volume 6,issue 1 , Vol. 6, Iss. 1, 2001-04 , pp.
Previous
Next